RT Journal Article
SR Electronic
T1 Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.13.20130088
DO 10.1101/2020.06.13.20130088
A1 Hernández-Mora, Miguel Górgolas
A1 Úbeda, Alfonso Cabello
A1 Pérez, Laura Prieto
A1 Álvarez, Felipe Villar
A1 Álvarez, Beatriz Álvarez
A1 Rodríguez Nieto, María Jesús
A1 Acosta, Irene Carrillo
A1 Fernández Ormaechea, Itziar
A1 Mohammed Al-Hayani, Aws Waleed
A1 Carballosa, Pilar
A1 Martínez, Silvia Calpena
A1 Ezzine, Farah
A1 González, Marina Castellanos
A1 Naya, Alba
A1 de las Heras, Marta López
A1 Rodríguez Guzmán, Marcel José
A1 Guijarro, Ana Cordero
A1 Lavado, Antonio Broncano
A1 Valcayo, Alicia Macías
A1 García, Marta Martín
A1 Martínez, Javier Bécares
A1 Roblas, Ricardo Fernández
A1 Piris Pinilla, Miguel Ángel
A1 Alen, José Fortes
A1 Pernaute, Olga Sánchez
A1 Bueno, Fredeswinda Romero
A1 Frades, Sarah Heili
A1 Barba Romero, Germán Peces
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130088.abstract
AB Introduction Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there is no data about the best moment for its administration along the course of the disease.Methods We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary endpoint was intubation or death after 24 hours of its administration. Patients received at least one dose of 400 mg intravenous tocilizumab during March 8-2020, through April 20-2020.Findings A total of 207 patients were studied and 186 analysed. The mean age was 65 years and 68% were male. A co-existing condition was present in 68 % of cases. At baseline, 114 (61%) required oxygen support with FiO2 >0.5 % and 72 (39%) ≤0.5%. Early administration of tocilizumab, when the need of oxygen support was still below FiO2 ≤0.5%, was significantly more effective than given it in advanced stages (FiO2 >0.5 %), achieving lower rates of intubation or death (13% vs 37% repectively, p<0·001).Interpretation The benefit of tocilizumab in severe SARS-Cov-2 pneumonia is only expected when it is administrated before the need of high oxygen support.Funding None.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Medical Committee Fundacion Jimenez DiazAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript.